|
WO2021048067A1
|
|
Stable crystalline apalutamide in pure form, and process for the preparation thereof
|
|
US2020407377A1
|
|
Process for the preparation of crisaborole in a stable crystal form
|
|
CN112272665A
|
|
Process for preparing sitagliptin
|
|
WO2019229625A1
|
|
Process for the preparation of apalutamide
|
|
CN112119058A
|
|
Process for the preparation of pimavanserin base
|
|
EP3774725A1
|
|
Process for the synthesis of optically active beta-amino alcohols
|
|
IT201900003839A1
|
|
STABLE AMORPHOUS APALUTAMIDE SYNTHESIS
|
|
US2020407355A1
|
|
Crystalline forms of venetoclax
|
|
WO2019123311A1
|
|
Process for preparing intermediates for the synthesis of optically active beta-amino alcohols by enzymatic reduction and novel synthesis intermediates
|
|
WO2019087035A1
|
|
Amorphous form of pimavanserin hemitartrate
|
|
CN111448203A
|
|
Efficient process for preparing cangrelor
|
|
WO2019020508A1
|
|
Method for the preparation of high-purity rucaparib
|
|
CA3065152A1
|
|
Process for the preparation of a novel umeclidinium synthesis intermediate
|
|
US10329311B1
|
|
Process for the preparation of crisaborole
|
|
EP3468951A1
|
|
Polymorph of nintedanib
|
|
EP3442957A1
|
|
"process for preparing intermediates useful in the synthesis of antifungal drugs"
|
|
EP3184513A1
|
|
Crystalline and amorphous forms of olaparib
|
|
US2018282339A1
|
|
Process for the preparation of the amorphous form of ibrutinib and novel crystalline form
|
|
WO2017077440A1
|
|
Novel pharmaceutical compositions comprising dabigatran
|
|
CN108137479A
|
|
It is used to prepare the method and novel synthetic intermediates of indane amine derivative
|
